💊 Ascendis Pharma Outperforms Expectations, Blueprint Medicines Falls After Mixed Q4 Results | Biotech Sector Insights
The U.S. CPI for January showed a year-over-year rise of 3%, exceeding expectations, which may influence monetary policy decisions. Initial jobless claims fell to 213,000, suggesting labor market resilience amidst economic uncertainties affecting the biotechnology sector.
Welcome to the MarketReader Minute.
Below are AI-generated insights on moves in the health care/biotechnology sector, powered by MarketReader technology.
Thursday, February 13
IBB [+0.5%]
iShares Biotechnology ETF
The iShares Biotechnology ETF (IBB) experienced a price increase of 0.5% since Wednesday. The U.S. Consumer Price Index for January showed a year-over-year rise of 3%, exceeding expectations, which may influence monetary policy decisions. Initial jobless claims fell to 213,000, suggesting labor market resilience amidst economic uncertainties affecting the biotechnology sector. Notably, Madrigal Pharmaceuticals attracted attention on social media due to significant options activity involving a $3 million call option transaction prior to the previous market close, with earnings expected on February 26. Among the ETF's holdings, Gilead Sciences partnered with Ideaya Biosciences to evaluate a treatment for non-small cell lung cancer, while Ascendis Pharma reported a narrower earnings loss and increased revenue, alongside a new share repurchase program and an upgraded price target from JPMorgan.